Markets
MYL

The Medicines Co. Posts Disappointing Preliminary Results - Analyst Blog

The Medicines CompanyMDCO announced disappointing preliminary worldwide net revenues for the first quarter of 2015. The company expects worldwide net revenues in the first quarter of 2015 to be in the range of $125 million to $130 million.

Revenues in the first quarter are expected to decline 26-29% from $177.2 million reported a year ago. Expected revenues are also below the current Zacks Consensus Estimate of $190 million.

The decrease in worldwide net revenue is primarily due to lower sales of Angiomax (EU trade name: Angiox). The company expects Angiomax revenues to be in the range of $97 million to $105 million compared with $155.7 million in the first quarter of 2014. The company attributes the likely decline in Angiomax sales to customers' current uncertainly regarding the product's patent exclusivity in the U.S. after Jun 2015

We remind investors that The Medicines Company is facing patent challenges for Angiomax from several companies including Hospira Inc. HSP and Mylan MYL . The company is entangled in patent infringement lawsuits with both Hospira and Mylan; an unfavorable ruling by the court could result in the entry of generic Angiomax as early as Jun 15, 2015.

Angiomax is approved for use in unstable angina patients undergoing percutaneous transluminal coronary angioplasty or percutaneous coronary intervention including patients with or at risk of heparin induced thrombocytopenia and thrombosis syndrome. The product accounted for almost 88% of the company's total revenues in 2014. Earlier-than-expected entry of generics will be a major setback for the company.

The company is set to release its final results for the first quarter of 2015 on May 5, 2015.

The Medicines Company carries a Zacks Rank #3 (Hold). A better-ranked stock in the health care sector is Cytokinetics, Incorporated CYTK sporting a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

HOSPIRA INC (HSP): Free Stock Analysis Report

MEDICINES CO (MDCO): Free Stock Analysis Report

MYLAN NV (MYL): Free Stock Analysis Report

CYTOKINETCS INC (CYTK): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

MYL CYTK

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More